The Evolution of Cancer Immunotherapy

被引:27
作者
Khan, Meshaal [1 ]
Maker, Ajay, V [1 ]
Jain, Shikha [1 ]
机构
[1] Univ Illinois, Oncol Dept, Chicago, IL 60607 USA
关键词
vaccines; immunotherapy; cancer; CAR-T; monoclonal antibodies; checkpoint inhibitor; HIGH-DOSE INTERLEUKIN-2; TALIMOGENE LAHERPAREPVEC; IMMUNE CHECKPOINTS; T-CELLS; THERAPY; VACCINES; BREAST; FUTURE; ANTIBODY; PD-1;
D O I
10.3390/vaccines9060614
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Immunotherapy has changed the environment of cancer treatment by providing new and efficacious therapy options for many solid and hematologic malignancies. Although not a new field of oncology, immunotherapy has quickly developed into one of the most flourishing fields in medicine. In this review article, we explore key discoveries which helped to shape our current understanding of the immune system's role in neoplasms. Many landmark developments include the advancements in checkpoint inhibitors, monoclonal antibodies, CAR-T cells and anti-cancer vaccines. We also explore the drawbacks and efficacy of various categories of immunotherapy. Ongoing investigations within immunotherapy, such as the gut microbiome, combining checkpoint inhibitors and gene sequencing, continue to personalize treatments for cancer patients, providing exciting and endless possibilities for the future.
引用
收藏
页数:11
相关论文
共 64 条
  • [1] Revisiting IL-2: Biology and therapeutic prospects
    Abbas, Abul K.
    Trotta, Eleonora
    Simeonov, Dimitre R.
    Marson, Alexander
    Bluestone, Jeffrey A.
    [J]. SCIENCE IMMUNOLOGY, 2018, 3 (25)
  • [2] The use of intravesical BCG in urothelial carcinoma of the bladder
    Alhunaidi, Omar
    Zlotta, Alexandre R.
    [J]. ECANCERMEDICALSCIENCE, 2019, 13
  • [3] Amgen Inc, 2015, IML TAL LAH SUSP INT
  • [4] [Anonymous], 1959, CELLULAR HUMORAL ASP
  • [5] [Anonymous], MICROBIOME IMMUNOTHE
  • [6] [Anonymous], PD-1/PD-L1 Landscape.
  • [7] Bota D, 2019, NEURO-ONCOLOGY, V21, P7
  • [8] Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
    Brudno, Jennifer N.
    Kochenderfer, James N.
    [J]. BLOOD REVIEWS, 2019, 34 : 45 - 55
  • [9] CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
    Buchbinder, Elizabeth I.
    Desai, Anupam
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (01): : 98 - 106
  • [10] CANCER - A BIOLOGICAL APPROACH .3. VIRUSES ASSOCIATED WITH NEOPLASTIC CONDITIONS
    BURNET, M
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1957, 1 (APR13): : 841 - 846